Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ719MR)

This product GTTS-WQ719MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ719MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13991MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ4547MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ1746MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ12862MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ7544MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ2271MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ7370MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ6608MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1728001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW